Enliven Therapeutics and Imara Announce Merger Agreement
October 13, 2022 16:35 ET
|
Imara, Inc.
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of...
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
April 05, 2022 06:45 ET
|
Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
Imara Reports Full Year 2021 Financial Results and Business Highlights
March 15, 2022 07:00 ET
|
Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
March 08, 2022 07:00 ET
|
Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 07:00 ET
|
Imara, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
January 25, 2022 07:00 ET
|
Imara, Inc.
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 14, 2021 07:00 ET
|
Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 22, 2021 07:00 ET
|
Imara, Inc.
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on...
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
November 16, 2021 07:00 ET
|
Imara, Inc.
Positive trend observed in transfusion-dependent subjects treated with higher dose tovinontrine for reduced transfusion burden Tovinontrine was generally well-tolerated in this patient population ...